Storage and handling
STORE AT 20⁰C - 25⁰C (68⁰F - 77⁰F). KEEP FROM FREEZING
STORE AT 20⁰C - 25⁰C (68⁰F - 77⁰F). KEEP FROM FREEZING
LincoMed® 100
(lincomycin injection)
For Intramuscular Use in Swine Only
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
LincoMed 100 contains lincomycin hydrochloride, an antibiotic produced by Streptomyces lincolnensis var. lincolnensis which is chemically distinct from all other clinically available antibiotics and is isolated as a white crystalline solid.
INDICATIONS FOR SWINE:
LincoMed 100 is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. This includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, Erysipelothrix and Mycoplasma spp.
It is also indicated for the treatment of mycoplasma pneumonia.
CONTRAINDICATIONS:
As with all drugs, use of LincoMed 100 is contraindicated in animals previously found to be hypersensitive to the drug.
Residue Warning: Swine intended for human consumption should not be slaughtered within 48 hours of latest treatment.
Human Warnings: Not for use in humans. Keep out of reach of children.
CAUTION:
If no improvement is noted within 48 hours, consult a veterinarian.
ADVERSE REACTIONS:
The intramuscular administration to swine may cause a transient diarrhea or loose stools. Although this effect has rarely been reported, one must be alert to the possibility that it may occur. Should this occur, it is important that the necessary steps be taken to prevent the effects of dehydration.
The Safety Data Sheet (SDS) contains more detailed occupational safety information. To report adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at
www.fda.gov/reportanimalae.
DOSAGE AND ADMINISTRATION:
For arthritis or mycoplasma pneumonia - 5 mg per pound of body weight intramuscularly once daily for three to seven days as needed. One mL per 20 lb body weight will provide 5 mg/lb.
For optimal results, initiate treatment as soon as possible.
As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe. No vial closure should be entered more than 20 times.
Each mL contains:
Lincomycin hydrochloride equivalent to lincomycin 100 mg; also benzyl alcohol 9.45 mg added as a preservative.
HOW SUPPLIED:
LincoMed is available in two concentrations: 100 mg/mL and 300 mg/mL.
100mg/mL: Supplied in 100 mL multiple dose vial.
300 mg/mL: For use in swine weighing 300 pounds or more. Supplied in 100 mL multiple dose vial.
STORE AT 20⁰C - 25⁰C (68⁰F - 77⁰F). KEEP FROM FREEZING
Approved by FDA under ANADA # 200-368
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 61133-6000 | LINCOMED 100 (LINCOMYCIN) INJECTION [BIMEDA, INC.] | 16 | Unmatched | 20240328_4c35730f-62b9-422f-8eb9-6cc4bbbeaaa7.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LINCOMYCIN HYDROCHLORIDE | ACTIVE INGREDIENT | M6T05Z2B68 | 5 | |
| LINCOMYCIN | ACTIVE MOIETY | BOD072YW0F | 5 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 61133-6000 | 61133-6000-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LINCOMYCIN HYDROCHLORIDE | M6T05Z2B68 | ACTIM |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| LINCOMYCIN | LINCOMYCIN HYDROCHLORIDE | Henry Schein, Inc. | a7692968-7ac8-48ab-89a4-27c7803e31f4 | 2025-10-31 | Boxed warning, Warnings, Adverse reactions | LINCOMYCIN HYDROCHLORIDE |
| Lincocin | LINCOMYCIN HYDROCHLORIDE | Pharmacia & Upjohn Company LLC | c01906fa-2c73-4c13-9765-2fd06628d263 | 2025-03-10 | Boxed warning, Warnings, Adverse reactions | LINCOMYCIN HYDROCHLORIDE |
| Lincomycin | LINCOMYCIN HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | 23f9608c-3126-35db-e063-6294a90af054 | 2024-10-08 | Boxed warning, Warnings, Adverse reactions | LINCOMYCIN HYDROCHLORIDE |
| Lincomycin | LINCOMYCIN HYDROCHLORIDE | Sagent Pharmaceuticals | 75e149cc-b668-427e-bae7-a0d215e4fb7a | 2023-03-20 | Boxed warning, Warnings, Adverse reactions | LINCOMYCIN HYDROCHLORIDE |
| Lincomycin | LINCOMYCIN HYDROCHLORIDE | XGen Pharmaceuticals DJB, Inc. | 61f4851d-d919-400d-912a-05eb9dca11d4 | 2022-10-14 | Boxed warning, Warnings, Adverse reactions | LINCOMYCIN HYDROCHLORIDE |
| lincomycin hydrochloride | LINCOMYCIN HYDROCHLORIDE | Gland Pharma Limited | c2b5be20-cc6f-4221-9d3e-3f8b5886cd05 | 2022-09-28 | Boxed warning, Warnings, Adverse reactions | LINCOMYCIN HYDROCHLORIDE |
Adverse event summaries are temporarily unavailable. Other product information remains available.